SCHEMBL14133776

SCHEMBL14133776

CCS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccco3)C(c3ccccc3F)C2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 11/20 0.84
▸ ALDH1A1 P00352 9/20 0.84
▸ KDM4E B2RXH2 7/20 0.84
▸ POLB P06746 4/20 0.84
▸ GAA P10253 3/20 0.84
▸ HTT P42858 2/20 0.84
▸ NPC1 O15118 1/20 0.76
▸ MAPT P10636 4/20 0.73
▸ HPGD P15428 3/20 0.73
▸ CYP3A4 P08684 1/20 0.73
▸ CYP2C9 P11712 1/20 0.73
▸ CYP2C19 P33261 1/20 0.73
▸ NPSR1 Q6W5P4 1/20 0.73
▸ LMNA P02545 1/20 0.64
▸ MEN1 O00255 4/20 0.56
▸ KMT2A Q03164 4/20 0.56
▸ GLA P06280 2/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ BCL2 P10415 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14133339 0.91 PKM (1.00) PKMALDH1A1KDM4EPOLBGAA
SCHEMBL14132749 0.90 NPC1 (0.77) PKMALDH1A1KDM4EPOLBGAA
SCHEMBL14133921 0.88 NPC1 (0.74) PKMALDH1A1KDM4EPOLBGAA
SCHEMBL14133778 0.88 PKM (0.86) PKMALDH1A1KDM4EPOLBGAA
SCHEMBL14132758 0.87 NPC1 (0.73) PKMALDH1A1KDM4EPOLBGAA
SCHEMBL14133529 0.87 PKM (0.85) PKMALDH1A1KDM4EPOLBGAA
SCHEMBL14136253 0.87 PKM (0.72) PKMALDH1A1KDM4EPOLBGAA
SCHEMBL14133534 0.85 PKM (0.68) PKMALDH1A1KDM4EPOLBGAA
SCHEMBL14133536 0.85 PKM (1.00) PKMALDH1A1KDM4EPOLBGAA
SCHEMBL14133452 0.85 KDM4E (0.68) PKMALDH1A1KDM4EPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 PKM 5/4885ALDH1A1 2476/4885KDM4E 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback